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PROSTATE	  FIELD	  CANCERIZATION	  –	  THINKING	  OUTSIDE	  THE	  TUMOR	  
	  
Shoshan, D.S., Bisoffi, M.	  
	  
Schmid College of Science and Technology, Biological Sciences/Biochemistry and Molecular Biology, Chapman University, Orange, CA 
17th	  Annual	  Chao	  Family	  Comprehensive	  Cancer	  Center	  Scien8ﬁc	  Retreat 
Tissue	  resec)on	  and	  H&E	  histology	  of	  
tumor	   (T)	   and	   histologically	   normal	  
adjacent	  prostate	  )ssue	  removed	  at	  1	  
cm	  from	  the	  tumor	  margin.	  
Sca@er	   plot	   of	   mRNA	  
e x p r e s s i o n 	   b y	  
microarray	   analysis	   in	  
t umo r	   and	   t umo r	  
adjacent	   histologically	  
n o r m a l 	   p r o s t a t e	  
)ssues.	   Factors	   of	  
par)cular	   interest	   are	  
indicated	   by	   arrows	  




•  Prostate	   cancer	   is	   the	   second	   most	   common	   cancer	   in	   American	   men	   with	   about	  
230,000	  new	  diagnoses	  and	  30,000	  deaths	  annually.	  Diagnosis	  by	  biopsy	  is	  hampered	  by	  
a	  30-­‐50%	  false-­‐negaSve	  rate	  due	  to	  small	  and	  easily	  missed	  cancer	  foci.	  
•  Field	   cancerizaSon	   denotes	   geneSc	   and/or	   biochemical	   molecular	   alteraSons	   in	  
phenotypically	  normal	  cells	  residing	  in	  histologically	  normal	  Sssues	  adjacent	  to	  prostate	  
tumors	  and	  may	  represent	  a	  temporal	  record	  of	  pathways	  underlying	  oncogenesis.	  
•  Our	   previous	   research	   has	   shown	   that	   the	   key	   transcripSon	   factor	   early	   growth	  
response	  1	  (EGR-­‐1)	  is	  up-­‐regulated	  at	  the	  mRNA	  level	  in	  ﬁeld	  cancerized	  human	  prostate	  
Sssues	  excised	  1cm	  from	  visible	  tumor	  margins	  (Haaland	  CM	  et	  al.	  2009;	   InternaSonal	  
Journal	  of	  Oncology	  (2009);	  35:537-­‐546).	  
HYPOTHESIS	  and	  OBJECTIVE	  
	  
•  We	  hypothesize	   that	   EGR-­‐1	   protein	   expression	  will	   be	   similarly	   elevated	   in	   cancerous	  
and	   histologically	   normal	   adjacent	   Sssues,	   which	   will	   support	   the	   concept	   of	   ﬁeld	  
cancerizaSon.	   We	   further	   hypothesize	   that	   markers	   of	   ﬁeld	   cancerizaSon,	   such	   as	  
EGR-­‐1,	   could	   serve	   as	   biomarkers	   of	   disease	   and	   improve	   early	   cancer	   detecSon	  
(diagnosis)	  at	  the	  Sme	  of	  biopsy.	  
•  The	   objecSve	   of	   this	   project	   is	   to	   determine	   and	   compare	   the	   expression	   of	   EGR-­‐1	  
protein	  in	  malignant	  and	  adjacent	  Sssues	  using	  quanStaSve	  methods.	  
EXPERIMENTAL	  METHODS	  
	  
Tissue	  Samples:	  Human	  prostate	  8ssues	  containing	  cancer	  cells	   (malignant)	  and	  matched	  adjacent	  8ssues	  devoid	  of	  
cancer	  cells	   (benign)	   from	  prostatectomies	  and	  matched	  biopsies	  were	  from	  the	  Coopera8ve	  Prostate	  Cancer	  Tissue	  
Resource	   (CPCTR)	  procured	  through	  the	  University	  of	  New	  Mexico	   (UNM)	  Health	  Sciences	  Center.	  The	  PC-­‐3	  cell	   line	  
was	   used	   for	   an8body	   control	   experiments.	   The	   present	   work	   is	   approved	   by	   Chapman	   University	   IRB	   protocol	  
#1415H024	  under	  biosafety	  level	  2	  (BSL2)	  approved	  prac8ces	  as	  per	  Ins8tu8onal,	  State,	  and	  Federal	  laws.	  
	  
Immunoﬂuorescence	  Microscopy:	   Immunoﬂuorescence	   (conven8onal)	  microscopy	  was	  performed	  using	   rabbit	  an8-­‐
human	   EGR-­‐1	   an8bodies	   (Santa	   Cruz	   Biotechnology),	   unspeciﬁc	   control	   IgG,	   and	   goat	   an8-­‐rabbit	   Alexa	   Fluor	   488	  
(green)	   conjugated	   an8bodies	   (Life	   Technologies)	   according	   to	   our	   previously	   published	   protocols	   (Jones	   AC	   et	   al.	  
2012;	  Prostate	  (2012);	  72:1159-­‐70).	  Fluorescent	  DAPI	  dye	  (blue)	  was	  used	  to	  visualize	  cell	  nuclei.	  
	  
QuanSﬁcaSon:	  Quan8ta8ve	   analysis	   (pixel	   densitometry)	  was	   performed	  using	   ImageJ64	   (provided	   by	   the	  Na8onal	  
Ins8tutes	   of	  Health)	   and	   graphs	  were	   generated	   using	  Microsoc	   Excel	   and	   JumpIn	   socware.	   Two	   signal	   acquisi8on	  
modes	  were	  applied:	  Whole	  ﬁeld	  analysis	  and	  region	  of	  interest	  analysis.	  
RESULTS	  
CONCLUSIONS	  	  and	  FUTURE	  RESEARCH	  
	  
•  EGR-­‐1	  protein	  expression	  is	  similar	  in	  cancerous	  (malignant)	  and	  in	  histologically	  normal	  
adjacent	  (benign)	  Sssues	  from	  both	  prostatectomy	  and	  biopsy	  Sssues.	  This	  supports	  the	  
concept	  of	  ﬁeld	  cancerizaSon	  and	  indicates	  a	  potenSal	  organ-­‐wide	  molecular	  change.	  	  
•  Future	  research	  includes	  improvements	  at	  the	  conceptual	  and	  technical	  level:	  	  
Ø  Increasing	  the	  number	  of	  cases	  and	  including	  disease-­‐free	  (age-­‐matched)	  prostate	  8ssues	  
Ø  Overcoming	  the	  autoﬂuorescence	  of	  prosta8c	  8ssues	  by	  the	  use	  of	  Alexa	  Fluor	  633-­‐conjugated	  2nd	  
an8bodies	  	  (far	  red)	  and	  increasing	  the	  resolu8on	  of	  detec8on	  by	  confocal	  microscopy	  
Ø  Design	  studies	  towards	  the	  clinical	  exploita8on	  of	  markers	  of	  ﬁeld	  canceriza8on.	  In	  par8cular,	  we	  
are	   interested	   in	   developing	   non-­‐invasive	   assessment	   schemes	   using	   novel	   and	   upcoming	  
technologies,	  including	  targeted	  nanopar8cle	  imaging	  modali8es	  
SIGNIFICANCE	  of	  RESEARCH	  
	  
Markers	  of	  ﬁeld	  cancerizaSon:	  	  
•  have	   the	   potenSal	   to	   lower	   the	   persistently	   high	   false	   biopsy	   negaSve	  
detecSon	  rate	  by	  expanding	  the	  target	  region.	  
•  may	  provide	  a	   target	   for	   repeat	  biopsy	   for	  paSents	  with	  high	  serum	  prostate	  
speciﬁc	  anSgen	  (PSA)	  but	  negaSve	  biopsy.	  
•  could	  improve	  clinical	  decision	  making,	  such	  as	  surgical	  intervenSon	  vs.	  acSve	  
surveillance.	  
Biopsy	  cores	  (small	  circles)	  miss	  the	  
two	   small	   cancer	   loci	   (white	  
irregular	  structures),	  while	  the	  ﬁeld	  
associated	   with	   the	   caner	   loci	  












































































































































































Tes)ng	   the	   speciﬁcity	   of	   the	   an)-­‐EGR-­‐1	   an)body	   on	   PC-­‐3	  
human	  prostate	  cancer	  cells.	  
Depic)on	   of	   the	   region	   of	  
interest	  analysis	  mode.	  
Representa)ve	   immunoﬂuorescent	   detec)on	   (green)	   of	   EGR-­‐1	   in	   two	   cases	   of	   malignant	   and	   benign	   )ssues	   of	  
prostatectomies	  and	  biopsies.	  
Quan)ta)ve	  immunoﬂuorescence	  data	  of	  EGR-­‐1	  in	  human	  malignant	  and	  benign	  prostate	  )ssues	  from	  prostatectomies	  and	  
biopsies	  by	  whole	  ﬁeld	  and	  region	  of	  interest	  analyses.	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